A Post-marketing Surveillance (PMS) Study to Evaluate the Safety and Effectiveness of NURTEC® ODT 75 mg (Rimegepant Sulfate) in Adult Migraine Patients in Korea.

The purpose of this study is to evaluate safety and effectiveness of NURTEC® ODT 75 mg (Rimegepant sulfate) in adult patients with acute treatment of migraine with or without aura and with preventive treatment of episodic migraine during the PMS period as required by the Korean ministry of food and drug safety (MFDS).

Start Date01 Mar 2027

Sponsor / Collaborator

Pfizer Inc.

NCT07751497

/ Not yet recruitingPhase 2IIT

A Randomized, Open-Label, Multi-Center Study of Vestibular Migraine Prevention: Rimegepant Versus Flunarizine Non-inferiority Study

Vestibular migraine is a common condition that causes repeated episodes of dizziness or vertigo, often with migraine headaches, sensitivity to light and sound, and nausea. It affects 1% to 2.7% of the general population and is one of the most frequent diagnoses in dizziness clinics. Despite its prevalence, there is very little high-quality evidence to guide preventive treatment.
This study compares two preventive treatments for vestibular migraine: rimegepant (a newer medication that blocks a protein called CGRP involved in migraine attacks) and flunarizine (a medication commonly used for vestibular migraine prevention in some countries). The study hypothesis is that rimegepant is not inferior to flunarizine in reducing the number of days with moderate-to-severe vestibular symptoms.
Approximately 400 adults aged 18 to 75 with definite vestibular migraine will be enrolled across multiple countries (China, Italy, Spain, and the United Kingdom). Participants will be randomly assigned in a 1:1 ratio to receive either rimegepant 75 mg once daily or flunarizine 10 mg once nightly for 12 weeks. The total study participation is 20 weeks, including a 4-week observation period, a 12-week treatment period, and a 4-week safety follow-up period. Participants will complete daily electronic diaries to record their symptoms throughout the study.
The primary outcome is the change in the number of moderate-to-severe vestibular symptom days from the observation period to weeks 13-16, comparing the two treatment groups. Secondary outcomes include treatment completion rates, changes in monthly migraine days, adverse events, and patient-reported outcomes including dizziness-related disability, anxiety, depression, and global impression of change.

Start Date01 Dec 2026

Sponsor / Collaborator-

NCT07812467

/ Not yet recruitingPhase 2IIT

A Phase II Randomized Controlled Clinical Trial of Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy in Patients With Oral/Oropharyngeal Squamous Cell Carcinoma

This study will evaluate whether adding rimegepant to standard neoadjuvant chemoimmunotherapy can improve treatment response in patients with primary or recurrent oral or oropharyngeal squamous cell carcinoma who are planned to undergo surgery.
Rimegepant blocks the receptor for calcitonin gene-related peptide, also known as CGRP. CGRP signaling may affect the tumor immune environment and the response of tumors to anticancer treatment.
The study includes an initial safety run-in stage involving 20 participants, followed by a randomized controlled stage involving 200 participants. During the randomized stage, participants will be assigned in a 1:1 ratio to receive standard neoadjuvant chemoimmunotherapy either with or without rimegepant. All participants will receive two cycles of neoadjuvant treatment followed by definitive or intended curative surgery.
The main outcome is the major pathological response rate, defined as 10% or less residual viable tumor in the surgical specimen. Other outcomes include pathological complete response, objective response, event-free survival, overall survival, changes in pain and quality of life, and treatment safety.

Start Date01 Oct 2026

Sponsor / Collaborator

Zhongshan Hospital Fudan University

[+1]

100 Clinical Results associated with Rimegepant Sulfate

100 Translational Medicine associated with Rimegepant Sulfate

100 Patents (Medical) associated with Rimegepant Sulfate

315

Literatures (Medical) associated with Rimegepant Sulfate

01 Dec 2026·Current Pain and Headache Reports

The Efficacy and Safety of Rimegepant Every Other Day as Preventive Treatment for Migraine: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Review

Author: Aladdin, Yasser ; Alshaikhi, Renad ; Alsharif, Joury ; Alamri, Lujain ; Barwais, Khalid ; Zagzoog, Nirmeen ; Aljadani, Hasen ; Attar, Ahmed ; Alzaid, Aldanah ; Alqsair, Abdalmajed ; Halabi, Mumen

BACKGROUND: Rimegepant is an oral CGRP receptor antagonist initially approved for the acute treatment of migraine, demonstrating rapid onset of action and a favorable tolerability profile. Recently, a limited number of randomized controlled trials have evaluated its prophylactic use. The aim of this systematic review and meta-analysis is to assess the effectiveness and safety of rimegepant as a preventive therapy for migraine. METHODOLOGY: This systematic review and meta-analysis followed PRISMA guidelines and was registered in PROSPERO (ID: CRD420251142208). We systematically searched Embase, PubMed, Scopus, Cochrane Central Register of Controlled Trials, Science Direct, and Clinical trials.gov from inception to March 2026. Keywords and MeSH terms were applied to identify randomized controlled trials assessing rimegepant for migraine prevention compared with placebo. Primary efficacy endpoints were the change from the observation period in the mean number of monthly migraine days over the entire study period ( Weeks 1–12 ), in the last month (Weeks 9–12 ), and in the first month (Weeks 1–4 ) Additional primary outcomes include the change from baseline in MSQ scores, the proportion of participants achieving ≥ 50% reduction in moderate to severe migraine attacks from the observation phase, and the reported safety outcomes. RESULTS: Screening of 792 articles yielded four randomized controlled trials comprising 2,365 participants. Rimegepant significantly reduced monthly migraine days compared with placebo : in the first four weeks (MD − 1.49; 95% CI: −1.84 to − 1.15, p < 0.00001; I²=31%), over the entire study period (MD − 0.98; 95% CI: − 1.33 to − 0.64, p < 0.00001; I²=43%), and in the last four weeks (MD − 0.91; 95% CI: −1.39 to − 0.44, p < 0.00001; I²=47%). Migraine Specific Quality-of-life score was improved (MD 4.36; 95% CI: 2.80 to 5.92, p < 0.00001; I²=9%). Responders rate of ≥ 50% reduction in the number of moderate-to-severe migraine attacks : in the last four weeks was higher in rimegepant group (RR 1.19; 95% CI: 1.04 to 1.36, p = 0.010;I²=0) and over the entire study period (RR 1.72; 95% CI: 0.86 to 3.34, p = 0.12;I²=92). Adverse events leading to discontinuation were higher in rimegepant (RR 1.76; 95% CI: 0.90 to 3.46, p = 0.10; I²=0). Rimegepant was associated with higher rates of nausea (RR 2.02; 95% CI: 1.02 to 4.00, p = 0.05; I²=0). CONCLUSION: To our knowledge, this is the first systematic review and meta-analysis evaluating rimegepant for migraine prophylaxis. Rimegepant showed statistically significant pooled effect in reducing monthly migraine days and was associated with improved quality of life. However, further studies are warranted to prove the clinical effectiveness of rimegepant as preventive treatment for migraine.

13 Oct 2026·NEUROLOGY

Systematic Review of Pharmacologic Treatment for Migraine Prevention in Adults

Review

Author: Fenton, Todd ; Ramanan, Vijay K. ; Fletcher, Jeff J. ; Botchway-Doe, Kylie A. ; Oskoui, Maryam ; Minen, Mia T. ; Potrebic, Sonja ; Hershey, Andrew D. ; Kessel, Shirley ; Loder, Elizabeth W. ; Gordon Perue, Gillian L. ; Jackson, Jeffrey L. ; Smith, Don B. ; Murren, Michelle ; Cooke, Lara J. ; Silberstein, Stephen D. ; Tanveer, Sarah ; Silsbee, Heather M. ; Pringsheim, Tamara ; Becker, Werner J. ; Burch, Rebecca ; Schwedt, Todd J.

BACKGROUND AND OBJECTIVES:

This systematic review (SR) provides updated evidence-based conclusions regarding the use of pharmacologic migraine prevention in adults to inform a new joint American Academy of Neurology (AAN) and American Headache Society practice guideline.

METHODS:

A multidisciplinary panel conducted an SR following the 2017 AAN Clinical Practice Guideline Process Manual. Randomized controlled trials evaluating pharmacologic preventive treatments for adults with episodic or chronic migraine were included. Searches encompassed MEDLINE, Embase, and ClinicalTrials.gov from database inception through June 6, 2024. Studies were screened in duplicate, with dual independent risk-of-bias assessment. Outcomes included change in monthly headache days, ≥50% responder rate, and validated patient-reported quality of life (QOL) measures. Raw mean differences, standardized mean differences, and risk ratios were calculated. A modified Grading of Recommendations Assessment, Development, and Evaluation process was used to classify certainty of evidence.

RESULTS:

A total of 217 studies met inclusion criteria. For episodic migraine, high-confidence evidence showed that galcanezumab and erenumab are more effective than placebo in reducing headache frequency. Moderate-confidence evidence supported benefit from atogepant, eptinezumab, fremanezumab, propranolol, topiramate, and valproate. Several additional oral agents including amitriptyline, bisoprolol, flunarizine, fluoxetine, levetiracetam, metoprolol, nifedipine, pizotifen, and telmisartan had low-confidence evidence suggesting possible benefit. For chronic migraine, high-confidence evidence supported reductions in headache frequency with fremanezumab, galcanezumab, and onabotulinumtoxinA. Moderate-confidence evidence supported benefit from atogepant, eptinezumab, erenumab, topiramate and valproate. Across both episodic and chronic migraine populations, erenumab, fremanezumab, galcanezumab, eptinezumab, rimegepant, atogepant, topiramate and onabotulinumtoxinA demonstrated improvements in patient-reported QOL outcomes on validated instruments. Evidence comparing active treatments was limited and generally of low or very low confidence, restricting conclusions about comparative effectiveness.

DISCUSSION:

This SR provides a comprehensive synthesis of evidence on pharmacologic migraine prevention in adults. High- and moderate-confidence findings confirm the efficacy of several established and newer preventive therapies and demonstrate improvements in patient-reported outcomes across multiple validated measures. These conclusions informed the development of evidence-based recommendations, presented in a companion publication, to guide clinicians in selecting preventive medications for adults with episodic and chronic migraine.

01 Oct 2026·HEADACHE

Systematic Review of Pharmacologic Treatment for Migraine Prevention in Adults

Review

Author: Fenton, Todd ; Ramanan, Vijay K. ; Fletcher, Jeff J. ; Potrebic, Sonja ; Oskoui, Maryam ; Minen, Mia T. ; Hershey, Andrew D. ; Kessel, Shirley ; Loder, Elizabeth W. ; Gordon Perue, Gillian L. ; Jackson, Jeffrey L. ; Smith, Don B. ; Murren, Michelle ; Cooke, Lara J. ; Silberstein, Stephen D. ; Tanveer, Sarah ; Silsbee, Heather M. ; Pringsheim, Tamara ; Burch, Rebecca ; Becker, Werner J. ; Schwedt, Todd J. ; Botchway‐Doe, Kylie A.

Abstract:

Background and Objectives:

This systematic review (SR) provides updated evidence‐based conclusions regarding the use of pharmacologic migraine prevention in adults to inform a new joint American Academy of Neurology (AAN) and American Headache Society practice guideline.

Methods:

A multidisciplinary panel conducted an SR following the 2017 AAN Clinical Practice Guideline Process Manual. Randomized controlled trials evaluating pharmacologic preventive treatments for adults with episodic or chronic migraine were included. Searches encompassed MEDLINE, Embase, and ClinicalTrials.gov from database inception through June 6, 2024. Studies were screened in duplicate, with dual independent risk‐of‐bias assessment. Outcomes included change in monthly headache days, ≥50% responder rate, and validated patient‐reported quality of life (QOL) measures. Raw mean differences, standardized mean differences, and risk ratios were calculated. A modified Grading of Recommendations Assessment, Development, and Evaluation process was used to classify certainty of evidence.

Results:

A total of 217 studies met inclusion criteria. For episodic migraine, high‐confidence evidence showed that galcanezumab and erenumab are more effective than placebo in reducing headache frequency. Moderate‐confidence evidence supported benefit from atogepant, eptinezumab, fremanezumab, propranolol, topiramate, and valproate. Several additional oral agents including amitriptyline, bisoprolol, flunarizine, fluoxetine, levetiracetam, metoprolol, nifedipine, pizotifen, and telmisartan had low‐confidence evidence suggesting possible benefit. For chronic migraine, high‐confidence evidence supported reductions in headache frequency with fremanezumab, galcanezumab, and onabotulinumtoxinA. Moderate‐confidence evidence supported benefit from atogepant, eptinezumab, erenumab, topiramate and valproate. Across both episodic and chronic migraine populations, erenumab, fremanezumab, galcanezumab, eptinezumab, rimegepant, atogepant, topiramate and onabotulinumtoxinA demonstrated improvements in patient‐reported QOL outcomes on validated instruments. Evidence comparing active treatments was limited and generally of low or very low confidence, restricting conclusions about comparative effectiveness.

Discussion:

This SR provides a comprehensive synthesis of evidence on pharmacologic migraine prevention in adults. High‐ and moderate‐confidence findings confirm the efficacy of several established and newer preventive therapies and demonstrate improvements in patient‐reported outcomes across multiple validated measures. These conclusions informed the development of evidence‐based recommendations, presented in a companion publication, to guide clinicians in selecting preventive medications for adults with episodic and chronic migraine.

109

News (Medical) associated with Rimegepant Sulfate

04 Aug 2026

·www.fiercepharma.com

Pfizer unveils additional $2.5B in planned cost savings through 2029

Pfizer will reduce its costs by $2.5 billion in another round of cutbacks, which will kick in next year and run through 2029. The New York company unveiled the plan in its second-quarter earnings report (PDF). The savings effort comes amid a quarter in which Pfizer topped expectations with a 3% revenue increase to $15 billion. The company raised its 2026 sales guidance at the midpoint by $500 million to a range of $60.5 billion to $62.5 billion. The additional cutbacks bring Pfizer’s total cost-savings target (PDF) to $9.7 billion through 2029. Of the new $2.5 billion effort, $1.5 billion is earmarked for optimizing the company’s manufacturing operations, with the remaining $1 billion added to Pfizer’s “cost realignment program.” In total, the cost realignment plan is designed to save the company $6.7 billion through the end of 2029. Pfizer is churning $500 million of the cost savings into R&D investment this year, it added. The manufacturing optimization effort is “focused on network structure changes, product portfolio enhancements and additional operational efficiencies,” Pfizer said. Overall, the cost savings will support “margin expansion through productivity gains” and provide “future growth opportunities,” Pfizer added. To install and execute the new cost savings, Pfizer will incur a one-time expenditure of $6 billion, with much of the figure going to severance, implementation and exit costs, in addition to non-cash expenditures for accelerated depreciation and asset write-downs. The program is a continuation of Pfizer’s reorganization, which kicked off in 2023 following its $43 billion acquisition of antibody-drug conjugate specialist Seagen. The buyout expanded Pfizer’s headcount to 88,000 at the end of that year and has since been in decline, falling to 75,000 at the end of 2025. As for Pfizer’s quarterly revenue surprise, analysts had expected a year-over-year decline, given the company’s 10% sales boom in the second quarter of 2025, which was attributed to contractual arrangements for the COVID products Comirnaty and Paxlovid. While the COVID products saw major dropoffs, including Paxlovid sales plummeting from $427 million in the second quarter of last year to $21 million in the same period this year, Pfizer’s growth products thrived, including blood thinner Eliquis, which was up 21%, and migraine therapy Nurtec, which saw an 18% increase. Pfizer’s cancer medications that were up included Orgovyx (+51%), Lorbrena (+41%) and Padcev (+23%), helping the oncology portfolio to a 9% bump. Even in the face of new competition from Alnylam and BridgeBio in ATTR-CM, Pfizer’s Vyndaqel family of drugs realized a 9% gain. Another positive was the rebound of RSV shot Abrysvo, which was up 46%. Interim chief financial officer Cecile Guegan said that Pfizer’s upgraded revenue guidance “reflects strong non-COVID product performance.” The uptick includes a $1.5 billion increase in expected sales from non-COVID products, along with a $1 billion reduction in the company’s projection of its COVID product sales, from $5 billion to $4 billion. “The performance that we have to date reflects the low infection level, mostly impacting Paxlovid,” Guegan added on a conference call Tuesday. “But we remain with our revenues for Comirnaty in the later part of the year, consistent with the vaccination season.”

Acquisition

27 Jul 2026

·www.eisai.com

Pfizer and Eisai Commence Co-promotion of “NURTEC®” for the Acute Treatment and Prophylaxis (Preventive Treatment) of Migraine

Our news releases are intended to disclose corporate information and are not intended for the promotion or advertising of prescription pharmaceuticals or investigational products, nor are they intended to provide medical advice. Please note that the information contained in news releases is current as of the date of publication.

05 May 2026

·firstwordpharma.com

After Vyndamax boost, Pfizer marks 2029 for next growth chapter

Pfizer is zeroing in on 2029 as the start of its next sustained growth cycle, with CEO Albert Bourla outlining a strategy recently bolstered by a patent reprieve for one of its key drugs."Our recent settlement agreements resolving infringement of patent related to Vyndamax have the potential to change the growth profile of the company significantly post-2028," Bourla said during Pfizer's first-quarter results presentation Tuesday. "This gives us greater confidence that starting in 2029, we will enter a five-year period of high-single-digit revenue CAGR."The transthyretin amyloid cardiomyopathy drug, part of the tafamidis franchise that brought in $6.4 billion in sales last year, was expected to see a drop in its US revenues starting in 2029 upon patent expiry. However, settlements with three generic drugmakers now extend protection until mid-2031, giving Pfizer more time to offset losses of exclusivity (LOEs) with newer assets."Always the strategy for LOEs was new and acquired products to do well… They are growing 22% this year," Bourla said. That basket of products generated $3.1 billion in the first quarter, and includes drugs such as cancer antibody-drug conjugate Padcev and CGRP antagonist Nurtec ODT/Vydura for migraine obtained through the prior acquisitions of Seagen and Biohaven, respectively."Without saying that that's the guidance, but if you multiply it by four…we are talking about over $12 billion this year and growing," he said.Revenues for Padcev were up 39% in the quarter to $591 million, while Nurtec ODT/Vydura generated $353 million, a gain of 41% compared to the year-ago period.$7B deal capacityMeanwhile, the company said it has roughly $7 billion to spend on deal-making, including about $1.65 billion in net proceeds from the recent sale of its stake in ViiV Healthcare.The new patent clarity on Vyndamax "actually gives us more confidence in our cash flow delivery over the next several years," said Chief Financial Officer Dave Denton, "and we constantly look at [business development] and understand what is appropriate strategically… to support the needs of the company."However, Pfizer isn't really looking to make any big, splashy moves for now. "We never say never… [but] right now, in the next few years, it is the time to execute on [the company's] AI transformation… And that requires not the disruption of mega mergers," Bourla said.More to follow.

AcquisitionPatent Infringement

100 Deals associated with Rimegepant Sulfate

External Link

KEGG	Wiki	ATC	Drug Bank
D10662 D10663	Rimegepant Sulfate	N02C	DB12457

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Acute migraine	South Korea	Pfizer Pharmaceuticals Korea Ltd.	24 Mar 2025
Migraine Disorders	United States	Pfizer Inc.	27 Feb 2020

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Paroxysmal Hemicrania	NDA/BLA	China	Pfizer Inc.	31 Mar 2026
Paroxysmal Hemicrania	NDA/BLA	China	Catalent Pharma Solutions Ltd.	31 Mar 2026
Migraine Without Aura	Phase 3	United States	Pfizer Inc.	11 Mar 2025
Migraine Without Aura	Phase 3	China	Pfizer Inc.	11 Mar 2025
Migraine Without Aura	Phase 3	Japan	Pfizer Inc.	11 Mar 2025
Migraine Without Aura	Phase 3	Argentina	Pfizer Inc.	11 Mar 2025
Migraine Without Aura	Phase 3	Canada	Pfizer Inc.	11 Mar 2025
Migraine Without Aura	Phase 3	Denmark	Pfizer Inc.	11 Mar 2025
Migraine Without Aura	Phase 3	Germany	Pfizer Inc.	11 Mar 2025
Migraine Without Aura	Phase 3	India	Pfizer Inc.	11 Mar 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05810038 (CTgov)	Phase 3	Migraine Disorders	787	DBT+Rimegepant (DBT Rimegepant)	ehocogcnor(tngbtzjzqx) = dnopqlbrfs jbpircjmrk (syxtpugyto, 0.14) View more	-	03 Sep 2026
				placebo+rimegepant (DBT Placebo)	ehocogcnor(tngbtzjzqx) = oljxhwiwzh jbpircjmrk (syxtpugyto, 0.14) View more
NCT05518123 (CTgov)	Phase 4	Migraine Disorders	962	rimegepant (DB Rimegepant)	sscthvlyvn(rqnrymcxft) = jsvgjinjuy ngbjzomncf (msewwhuigt, znlnawfdrb - dwhonntnrc) View more	-	22 May 2026
				placebo+rimegepant (DB Placebo)	sscthvlyvn(rqnrymcxft) = prmqrduqws ngbjzomncf (msewwhuigt, ofmftjrhkl - qjhsxcnyzi) View more
NCT06221111 (CTgov)	Phase 2	Abdominal Pain \| Irritable Bowel Syndrome	39	Rimegepant 75 MG [Nurtec] (Rimegepant)	ekbiqsrpit(pfmzrwqovp) = hyamsjnzmn rrfqauuquq (vjkicbefkt, owkygdoefq - xkwjscafqt) View more	-	22 May 2026
				Rimegepant 75 MG [Nurtec] (Placebo)	ekbiqsrpit(pfmzrwqovp) = ssjfrkilen rrfqauuquq (vjkicbefkt, dnaaczeerh - qyzostcyur) View more
NCT05518123 (AAN2026)	Phase 3	Migraine Disorders	595	Rimegepant 75 mg EOD	fpnfyoitcm(ovrvuqvrpx) = joxevseqsn rzlctbqxsk (zxmtiotzjp ) View more	Positive	25 Apr 2026
NCT05217927 (AAN2026)	Phase 4	Migraine Disorders	692	Rimegepant 75 mg EOD	wehwvtfvcn(rlvrsvlfqk) = ljurhorndw azouyrinmp (lmlwvewrdb ) View more	Positive	25 Apr 2026
				Rimegepant 75 mg QD	wehwvtfvcn(rlvrsvlfqk) = mipddhvqla azouyrinmp (lmlwvewrdb ) View more
NCT05518123 (AAN2026)	Phase 4	Migraine Disorders	652	Rimegepant 75 mg orally disintegrating tablet (ODT) taken once every other day (EOD)	zxzsuqayfp(lkbvxbnidz): P-Value = 0.0003 View more	Positive	25 Apr 2026
				Placebo
NCT05509400 (NCT05509400, AAN2026)	Phase 3	Migraine Disorders	552	Rimegepant 75 mg	uenniqdvwr(dbioswsdpn) = jeubswwpwd jlrkvtjfkv (jowxbsjpyz ) View more	Positive	25 Apr 2026
NCT03461757 \| NCT03237845 \| NCT03235479 (Pubmed \| Headache)	Phase 3	Migraine Disorders Black or African American	696	Rimegepant 75 mg	kvlwfkwvqf(bhepqfkphq) = vbtscvqlsz uynmiaiiis (xjtrwlwesb ) View more	Positive	06 Feb 2026
				Placebo	kvlwfkwvqf(bhepqfkphq) = srwzjffgtr uynmiaiiis (xjtrwlwesb ) View more
NCT05217927 (CTgov)	Phase 4	Migraine Disorders	1,415	Placebo+Rimegepant (DB Rimegepant/ Placebo)	sgtejrsvft(vfmwzdfdvp) = btfnhlqxpa dthcnzyrew (wpobnskqkd, tjvwgzgrnz - vcboliblla) View more	-	16 Dec 2025
				ODT (DB Rimegepant)	sgtejrsvft(vfmwzdfdvp) = yffeumbqex dthcnzyrew (wpobnskqkd, ecpwnieuvv - fvlpmkfefv) View more
NCT05207865 (Pubmed \| J Headache Pain)	Phase 4	Migraine Disorders	250	Rimegepant 75 mg QD	ujtrmcjbtx(ivmdswhtrp) = idhjevhybu xdevtgqkjw (npczufvozf ) View more	Positive	09 Dec 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis